Skip to main content
CGEM
NASDAQ Life Sciences

Zipalertinib Combo Cuts Risk of Progression by 50% in First-Line EGFR Exon 20 NSCLC

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$21.11
Mkt Cap
$1.325B
52W Low
$5.68
52W High
$23.19
52W Position info
272% above low
Off High info
9.0% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

CGEM has more than doubled off its 52-week low of $5.68.

Summary

Full Phase 3 REZILIENT3 data show zipalertinib plus chemotherapy extended median progression-free survival to 14.5 months versus 8.5 months for chemo alone (HR=0.50, P=0.00015) in first-line EGFR exon 20 insertion NSCLC. Objective response rate was 65.0% vs 40.3% (P<0.0001), with a longer median duration of response (14.2 vs 9.9 months). Interim overall survival favored the combo (HR=0.72) but is immature at 30% events. Safety showed more Grade ≥3 AEs (87.1% vs 54.4%), driven by manageable hematologic toxicity. This follows the August 12 announcement that the trial met its primary endpoint; today's release provides the detailed dataset presented at WCLC. The magnitude of PFS benefit and response improvement supports a potential first-line label expansion, a key value driver for Cullinan's zipalertinib franchise.

At the time of this announcement, CGEM was trading at $21.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.68 to $23.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

CGEM - Latest Insights

CGEM
Nov 12, 2026, 4:30 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.35
Real-time Price: $9.28 info
Change: -$1.07 (-10%) info
Market Cap: $602.142M info
CGEM
Nov 08, 2026, 10:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.51
Real-time Price: $9.28 info
Change: -$2.23 (-19%) info
Market Cap: $602.142M info
CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $9.28 info
Change: -$4.07 (-30%) info
Market Cap: $602.142M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $9.28 info
Change: -$5.27 (-36%) info
Market Cap: $602.142M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $9.28 info
Change: -$7.60 (-45%) info
Market Cap: $602.142M info